194 related articles for article (PubMed ID: 32322878)
1. Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease.
Levhar N; Ungar B; Kopylov U; Fudim E; Yavzori M; Picard O; Amariglio N; Chowers Y; Shemer-Avni Y; Mao R; Chen MH; Ye Z; Eliakim R; Ben-Horin S
Inflamm Bowel Dis; 2020 Aug; 26(9):1330-1339. PubMed ID: 32322878
[TBL] [Abstract][Full Text] [Related]
2. Immortalized Epstein-Barr virus-positive B-cell lines obtained by prolonged culture of peripheral blood mononuclear cells from human immunodeficiency virus type 1-positive patients.
Ruibal-Ares B; Belmonte L; Baré P; Scolnik M; Palacios MF; Bayo-Hanza C; Galmarini CM; Mendez G; de Bracco MM
J Hum Virol; 2001; 4(4):200-13. PubMed ID: 11694848
[TBL] [Abstract][Full Text] [Related]
3. Anti-TNFα therapy for inflammatory bowel diseases is associated with Epstein-Barr virus lytic activation.
Lapsia S; Koganti S; Spadaro S; Rajapakse R; Chawla A; Bhaduri-McIntosh S
J Med Virol; 2016 Feb; 88(2):312-8. PubMed ID: 26307954
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients.
Petrara MR; Cattelan AM; Zanchetta M; Sasset L; Freguja R; Gianesin K; Cecchetto MG; Carmona F; De Rossi A
J Clin Virol; 2012 Mar; 53(3):195-200. PubMed ID: 22209290
[TBL] [Abstract][Full Text] [Related]
5. Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.
Wilson AD; Morgan AJ
J Virol; 2002 May; 76(10):5071-81. PubMed ID: 11967323
[TBL] [Abstract][Full Text] [Related]
6. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals.
Metes D; Storkus W; Zeevi A; Patterson K; Logar A; Rowe D; Nalesnik MA; Fung JJ; Rao AS
Transplantation; 2000 Nov; 70(10):1507-15. PubMed ID: 11118098
[TBL] [Abstract][Full Text] [Related]
8. Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity.
Gudgeon NH; Taylor GS; Long HM; Haigh TA; Rickinson AB
J Virol; 2005 May; 79(9):5477-88. PubMed ID: 15827162
[TBL] [Abstract][Full Text] [Related]
9. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis.
Pender MP; Csurhes PA; Lenarczyk A; Pfluger CM; Burrows SR
J Neurol Neurosurg Psychiatry; 2009 May; 80(5):498-505. PubMed ID: 19015225
[TBL] [Abstract][Full Text] [Related]
10. Primary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells.
MacArthur GJ; Wilson AD; Birchall MA; Morgan AJ
J Virol; 2007 May; 81(9):4766-75. PubMed ID: 17314172
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease.
Sankaran-Walters S; Ransibrahmanakul K; Grishina I; Hung J; Martinez E; Prindiville T; Dandekar S
J Clin Virol; 2011 Jan; 50(1):31-6. PubMed ID: 21035384
[TBL] [Abstract][Full Text] [Related]
12. Establishment of EBV-Infected Lymphoblastoid Cell Lines.
Nagy N
Methods Mol Biol; 2017; 1532():57-64. PubMed ID: 27873266
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture.
Sharif-Askari E; Fawaz LM; Tran P; Ahmad A; Menezes J
J Natl Cancer Inst; 2001 Nov; 93(22):1724-32. PubMed ID: 11717333
[TBL] [Abstract][Full Text] [Related]
14. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
15. Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes.
Rochford R; Hobbs MV; Garnier JL; Cooper NR; Cannon MJ
Proc Natl Acad Sci U S A; 1993 Jan; 90(1):352-6. PubMed ID: 8380497
[TBL] [Abstract][Full Text] [Related]
16. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection.
Tsuge I; Morishima T; Kimura H; Kuzushima K; Matsuoka H
J Med Virol; 2001 Jun; 64(2):141-8. PubMed ID: 11360246
[TBL] [Abstract][Full Text] [Related]
17. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 and Epstein-Barr virus induction by cyclosporine A: potential role in lymphoproliferative disease.
Tanner JE; Menezes J
Blood; 1994 Dec; 84(11):3956-64. PubMed ID: 7949151
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporin A up-regulates and activates protein kinase C-zeta in EBV-infected and EBV-transformed human B-cells.
Chen C; Johnston TD; Jeon H; Gedaly R; McHugh P; Ranjan D
J Surg Res; 2009 May; 153(1):156-61. PubMed ID: 18486150
[TBL] [Abstract][Full Text] [Related]
20. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease.
Tanner JE; Alfieri C
Leuk Lymphoma; 1996 May; 21(5-6):379-90. PubMed ID: 9172802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
